Healthcare > Pharmaceuticals & Biotechnology
•2432 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (2432)
| Company | Market Cap | Price |
|---|---|---|
|
CGEN
Compugen Ltd.
COM701 and GS-0321 are monoclonal antibody therapeutics in development, aligning with Monoclonal Antibody Therapeutics.
|
$220.74M |
$2.37
+12.09%
|
|
NVCT
Nuvectis Pharma, Inc.
Nuvectis' lead asset NXP900 is a cancer-targeting therapy (SRC/YES1 kinase inhibitor), placing the company in Biotech - Oncology.
|
$215.87M |
$8.55
+0.23%
|
|
ZNTL
Zentalis Pharmaceuticals, Inc.
Zentalis is a biotech company focused on oncology therapies, centered on cancer indications with their lead asset azenosertib.
|
$213.52M |
$2.96
-6.49%
|
|
FENC
Fennec Pharmaceuticals Inc.
Direct product in oncology/supportive care with FDA-approved PEDMARK therapy for cisplatin-induced ototoxicity.
|
$210.13M |
$7.74
+2.45%
|
|
VYGR
Voyager Therapeutics, Inc.
Voyager’s core offerings are gene therapies and gene-delivery platforms, including APOE and tau-targeted approaches.
|
$208.56M |
$3.77
-1.44%
|
|
CRGX
CARGO Therapeutics, Inc. Common Stock
CRGX's core offerings are oncology CAR-T therapies (firi-cel, CRG-23), placing it in Biotech - Oncology.
|
$206.13M |
$4.47
|
|
CABA
Cabaletta Bio, Inc.
Core product category: CAR-T cell therapy platform (CARTA) and rese-cel directly produced by Cabaletta.
|
$201.22M |
$2.21
+6.25%
|
|
SGMT
Sagimet Biosciences Inc.
Sagimet's lead and second FASN inhibitors (denifanstat, TVB-3567) are oral small-molecule therapeutics, directly aligning with this tag.
|
$199.68M |
$6.16
-1.68%
|
|
AVTX
Avalo Therapeutics, Inc.
AVTX-9.00 is an anti-IL-1β monoclonal antibody, directly fitting Monoclonal Antibody Therapeutics.
|
$198.07M |
$15.03
-3.90%
|
|
DERM
Journey Medical Corporation
Emrosi is an oral small molecule therapeutic (minocycline extended-release) and represents Journey Medical's flagship product launched in 2025.
|
$195.27M |
$8.01
-4.19%
|
|
GALT
Galectin Therapeutics Inc.
Lead cancer therapy program belapectin demonstrates oncology-focused Biotech activity and immuno-oncology potential.
|
$194.74M |
$3.04
-3.33%
|
|
SLGL
Sol-Gel Technologies Ltd.
SGT-610 and SGT-210 target rare dermatologic diseases (Gorlin syndrome, Darier disease), aligning with the Rare Diseases investable theme.
|
$193.61M |
$68.59
+0.41%
|
|
TARA
Protara Therapeutics, Inc.
TARA-2.00 is a cell therapy platform, representing the company’s lead product modality.
|
$193.30M |
$5.01
-0.50%
|
|
RNAC
Cartesian Therapeutics, Inc.
Lead platform is an autologous cell therapy using mRNA CAR-T, a direct cell-therapy product line.
|
$192.94M |
$7.41
+0.68%
|
|
CRDF
Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company focused on oncology therapeutics, with its lead asset targeting cancer (onvansertib).
|
$191.59M |
$2.89
+3.58%
|
|
IMDX
Insight Molecular Diagnostics Inc.
IMDX maintains an oncology pipeline (DetermaIO, DetermaCNI), placing it in Biotech - Oncology.
|
$189.89M |
$6.61
-0.23%
|
|
CBIO
Crescent Biopharma, Inc.
Crescent Biopharma focuses on oncology therapeutics, explicitly mentioning next-gen cancer biologics and its lead PD-1 x VEGF bispecific and ADCs.
|
$187.69M |
$13.45
+7.56%
|
|
CNFN
CFN Enterprises Inc.
CNFN's Ranco segment operates as a contract manufacturer/co-packer and white-label producer for clients.
|
$186.35M |
$1.57
|
|
ALEC
Alector, Inc.
Latozinemab and AL101 are monoclonal antibody therapeutics in the pipeline.
|
$186.23M |
$1.84
+1.10%
|
|
CHRS
Coherus Oncology, Inc.
LOQTORZI is a differentiated PD-1 monoclonal antibody and commercial oncology product, aligning with Monoclonal Antibody Therapeutics.
|
$185.96M |
$1.61
-3.01%
|
|
EDIT
Editas Medicine, Inc.
Core product category: in vivo gene therapy using Editas's gene-editing platform (AsCas12a) delivered via targeted lipid nanoparticles (tLNP).
|
$178.94M |
$2.04
+2.76%
|
|
TLSA
Tiziana Life Sciences Ltd
TLSA's lead product Foralumab is a fully human monoclonal antibody therapeutic, placing the company in Monoclonal Antibody Therapeutics.
|
$177.91M |
$1.68
+15.52%
|
|
PRQR
ProQR Therapeutics N.V.
ProQR's Axiomer platform uses oligonucleotide-based RNA editing (EONs) to direct ADAR-mediated editing.
|
$177.72M |
$1.67
+5.38%
|
|
TKNO
Alpha Teknova, Inc.
Teknova provides GMP-grade manufacturing for clinical-relevant reagents and custom solutions, aligning with contract manufacturing services.
|
$177.67M |
$3.31
-10.54%
|
|
MDWD
MediWound Ltd.
MediWound's core products are enzymatic proteins/enzymes (NexoBrid, EscharEx) used for wound debridement, aligning with Recombinant Proteins & Enzymes.
|
$176.73M |
$16.32
-6.04%
|
|
CRBU
Caribou Biosciences, Inc.
Company is developing gene-editing gene therapy platforms (CRISPR-based chRDNA) for therapeutic applications.
|
$176.00M |
$1.85
-2.12%
|
|
HUMA
Humacyte, Inc.
ATEV platform relates to tissue engineering/cell therapy platforms; relevant biotech tag.
|
$175.79M |
$1.11
+1.36%
|
|
MIST
Milestone Pharmaceuticals Inc.
Milestone's lead candidate etripamil is a cardiovascular drug developed for PSVT and AFib-RVR.
|
$174.24M |
$2.23
+9.02%
|
|
CATX
Perspective Therapeutics, Inc.
Company directly develops and provides radiopharmaceuticals using alpha-emitting Lead-212 for targeted cancer therapy and diagnostic imaging via 203Pb in a theranostic approach.
|
$173.03M |
$2.34
-5.65%
|
|
SRZN
Surrozen, Inc.
Direct ophthalmic drug development focusing on retinal diseases using Wnt-modulating antibodies.
|
$171.41M |
$20.00
|
|
PEPG
PepGen Inc.
PepGen's PGN-EDODM1 is an oligonucleotide therapeutic targeting DM1, aligning directly with Oligonucleotide Therapeutics.
|
$170.56M |
$5.21
+4.51%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$169.72M |
$6.21
+1.22%
|
|
NTHI
Neonc Technologies Holdings, Inc.
Rare Pediatric Disease designation aligns with pediatric brain tumor program (NEO100 pediatric).
|
$167.26M |
$8.82
+1.38%
|
Showing page 14 of 25 (2432 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
